Ultromics raises $55m in Series C funding led by Lightrock, Legal and General, and Allegis Capital to expand its artificial intelligence diagnostics platform.
The Oxford spinout secured backing from a group of healthcare investors to scale its EchoGo heart disease detection technology.
An artificial intelligence health technology company that develops automated diagnostic platforms for cardiology.
Ultromics, an artificial intelligence health technology startup based in Oxford, has secured $55m in Series C funding to advance its EchoGo diagnostic platform. The financing round was led by Lightrock, Legal and General, and Allegis Capital, with participation from Oxford Science Enterprises, GV, Blue Venture Fund, Oxford University, UPMC Enterprises, and University of Chicago Medicine.
The capital will be directed toward nationwide expansion, particularly across the US Midwest and other strategic markets, alongside the development of new product offerings for additional cardiac conditions. Ultromics intends to use the funds to strengthen partnerships with healthcare organisations and expand its commercial footprint.
The company's flagship EchoGo platform analyses routine echocardiograms to identify early signs of heart failure with preserved ejection fraction and cardiac amyloidosis. By integrating into existing clinical workflows without requiring new hardware, the technology aims to address persistent diagnostic gaps and improve patient outcomes globally.
From the founder
"Hospitals already possess the data; they just lack the tools to unlock its full diagnostic potential."
Ross Upton
Founder at Ultromics
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Lightrock
Legal & General
Allegis Capital
Legal and General
Oxford Science Enterprises
GV
Blue Venture Fund
Oxford University
UPMC Enterprises
University of Chicago Medicine
